Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: March 9, 2026
Subject: Update on Share Repurchase Programme
Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing reports on the execution of a share repurchase programme initiated on February 4, 2026, under the EU Market Abuse Regulation (MAR) and Safe Harbour Rules.
Key Financial Metrics and Capital Allocation
This filing focuses on capital allocation via share buybacks rather than operational financial performance (revenue, profit, or cash flow).
| Metric | Value |
|---|---|
| Total Repurchase Programme Cap | DKK 15 billion |
| Programme Duration | 12 months (Feb 4, 2026 – Feb 4, 2027) |
| Specific Tranche Cap (Feb 4 – May 4, 2026) | DKK 3.8 billion |
| Total Shares Repurchased (as of Mar 6, 2026) | 5,334,992 B shares |
| Total Transaction Value (as of Mar 6, 2026) | DKK 1,472,797,094 |
| Average Purchase Price | DKK 276.06 per B share |
| Treasury Shares Held | 22,724,791 B shares (0.5% of share capital) |
Material Changes and Transaction Details
Since the last announcement on March 2, 2026, the company executed daily repurchases through March 6, 2026. The filing details the following recent activity:
- March 2: 265,000 shares at DKK 235.47 (Value: DKK 62.4M)
- March 3: 264,992 shares at DKK 234.56 (Value: DKK 62.2M)
- March 4: 260,000 shares at DKK 241.02 (Value: DKK 62.7M)
- March 5: 250,000 shares at DKK 248.29 (Value: DKK 62.1M)
- March 6: 250,000 shares at DKK 251.23 (Value: DKK 62.8M)
The average purchase price has risen from the initial tranche average, reflecting market price fluctuations during the period.
Guidance, Outlook, and Risks
Outlook: Novo Nordisk expects to continue repurchasing B shares up to the total programme limit of DKK 15 billion over the 12-month period starting February 4, 2026. As of March 6, 2026, approximately DKK 1.47 billion has been utilized, leaving significant capacity remaining in the current tranche and the overall programme.
Risks and Contingencies: The filing does not disclose new operational risks or contingencies. The repurchase programme is subject to market conditions and regulatory compliance under the EU Safe Harbour Rules.
Investor Verification Checklist
- Verify the remaining capacity of the DKK 15 billion programme against the DKK 1.47 billion already spent.
- Monitor the average purchase price trend (currently DKK 276.06) relative to the current market price of B shares.
- Confirm the impact of the 0.5% treasury share holding on earnings per share (EPS) calculations in future reports.
- Check the company website (novonordisk.com) for daily transaction details as required by the filing.